Product
Caplacizumab
Aliases
ALX-0081, Cablivi®
Name
Cablivi
INN Name
caplacizumab
FDA Approved
Yes
6 clinical trials
1 organization
4 indications
1 document
Indication
Thrombotic Thrombocytopenic PurpuraIndication
Thrombotic thrombocytopenic purpuraIndication
Immune Thrombocytopenic PurpuraIndication
Immune Thrombotic ThrombocytopeniaClinical trial
An Open-label, Single-arm, Multicenter Study to Evaluate the Efficacy and Safety of Caplacizumab and Immunosuppressive Therapy Without Firstline Therapeutic Plasma Exchange in Adults With Immune-mediated Thrombotic Thrombocytopenic PurpuraStatus: Recruiting, Estimated PCD: 2024-12-13
Clinical trial
A Phase III Double-blind, Randomized, Parallel Group, Multicenter Placebo-controlled Trial to Study the Efficacy and Safety of Caplacizumab in Patients With Acquired Thrombotic Thrombocytopenic PurpuraStatus: Completed, Estimated PCD: 2017-08-01
Clinical trial
An Open-label Multicenter Trial to Study the Efficacy and Safety of Caplacizumab in Japanese Patients With Acquired Thrombotic Thrombocytopenic PurpuraStatus: Completed, Estimated PCD: 2021-05-19
Clinical trial
Retrospective Data Collection of Pediatric Patients With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP) Treated With CaplacizumabStatus: Completed, Estimated PCD: 2022-10-28
Clinical trial
A Phase II, Single-blind, Randomized, Placebo-controlled Trial to Study the Efficacy and Safety of Anti-von Willebrand Factor Nanobody Administered as Adjunctive Treatment to Patients With Acquired Thrombotic Thrombocytopenic PurpuraStatus: Completed, Estimated PCD: 2014-03-01
Clinical trial
Impact of Acute iTTP Therapies on Long Term Neurologic and Cognitive Outcomes in iTTP SurvivorsStatus: Not yet recruiting, Estimated PCD: 2027-05-01
Document
DailyMed Label: CabliviOrganization
Genzyme Corporation